Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Abiraterone Krka, abiraterone acetate, Date of authorisation: 24/06/2021, Revision: 5, Status: Authorised

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-14 January 2026

Referral: Oxbryta, voxelotor Article 20 procedures European Commission final decision, 16/10/2025, 09/12/2025, 16/01/2026

Human medicines European public assessment report (EPAR): Ifirmacombi, irbesartan,hydrochlorothiazide, Date of authorisation: 04/03/2011, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Irbesartan/Hydrochlorothiazide Teva, irbesartan,hydrochlorothiazide, Date of authorisation: 26/11/2009, Revision: 25, Status: Authorised

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12 - 15 January 2026

Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 June 2025, 15:00 (CEST) to 12 June 2025, 17:30 (CEST)

Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 June 2024, 15:00 (CEST) to 18 June 2024, 17:30 (CEST)

Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 July 2023, 15:00 (CEST) to 20 July 2023, 17:00 (CEST)